Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Calcineurin inhibitor-based immunosuppression and COVID-19: Results from a multidisciplinary cohort of patients in Northern Italy
Microorganisms, Volume 8, No. 7, Article 977, Year 2020
Notification
URL copied to clipboard!
Description
The role of immunosuppression in SARS-CoV-2-related disease (COVID-19) is a matter of debate. We here describe the course and the outcome of COVID-19 in a cohort of patients undergoing treatment with calcineurin inhibitors. In this monocentric cohort study, data were collected from the COVID-19 outbreak in Italy up to April 28th 2020. Patients were followed at our hospital for solid organ transplantation or systemic rheumatic disorders (RMDs) and were on calcineurin inhibitor (CNI)-based therapy. Selected patients were referred from the North of Italy. The aim of our study was to evaluate the clinical course of COVID-19 in this setting. We evaluated 385 consecutive patients (220 males, 57%; median age 61 years, IQR 48–69); 331 (86%) received solid organ transplantation and 54 (14%) had a RMD. CNIs were the only immunosuppressant administered in 47 patients (12%). We identified 14 (4%) COVID-19 patients, all transplanted, mainly presenting with fever (86%) and diarrhea (71%). Twelve patients were hospitalized and two of them died, both with severe comorbidities. No patients developed acute respiratory distress syndrome or infectious complications. The surviving 10 patients are now fully recovered. The clinical course of COVID-19 patients on CNIs is generally mild, and the risk of superinfection seems low. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Authors & Co-Authors
Cavagna, L.
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Seminari, Elena Maria
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Zanframundo, Giovanni
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Montecucco, Carlomaurizio
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Bertani, Alessandro
Italy, Palermo
Istituto Mediterraneo Per I Trapianti e Terapie ad Alta Specializzazione
Sambataro, Gianluca
Italy, Catania
Azienda Ospedaliero Universitaria Policlinico G.rodolico - San Marco
Vancheri, Carlo
Italy, Catania
Azienda Ospedaliero Universitaria Policlinico G.rodolico - San Marco
Biglia, Alessandro
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Monti, Maria Cristina
Italy, Pavia
Università Degli Studi Di Pavia
Turco, Annalisa
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Zuccaro, Valentina
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Codullo, Veronica
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Gnecchi, Massimiliano
Italy, Pavia
Fondazione Irccs Policlinico San Matteo
Italy, Pavia
Università Degli Studi Di Pavia
Statistics
Citations: 43
Authors: 13
Affiliations: 5
Identifiers
Doi:
10.3390/microorganisms8070977
ISSN:
20762607
Research Areas
Covid
Health System And Policy
Study Design
Cohort Study
Study Approach
Quantitative